Increased Burden of Familial-associated Early-onset Cancer Risk among Latino Americans Compared to non-Latino Whites.

Qianxi Feng, MPH [1], Eric Nickels, MD [1,2], Ivo S. Muskens, MD [1], Adam J. de Smith, PhD [1], W. James Gauderman, PhD [1], Amy C. Yee, MPH [1], Charite Ricker, MS, CGC [3], Thomas Mack, MD [1], Andrew D. Leavitt, MD [4], Lucy A. Godley, MD, PhD [5], Joseph L. Wiemels, PhD [1]

Affiliations of authors:

[1] Department of Preventive Medicine, USC Keck School of Medicine, Los Angeles, CA

[2] Children's Hospital Los Angeles, Los Angeles, CA

[3] Norris Comprehensive Cancer Center, USC Keck School of Medicine, Los Angeles, CA

[4] Departments of Medicine and Laboratory Medicine, University of California, San Francisco, San Francisco, CA

[5] Departments of Medicine and Human Genetics, The University of Chicago, Chicago, IL

Correspondence to:

Joseph L. Wiemels

Professor, Department of Preventive Medicine

Center for Genetic Epidemiology

1450 Biggy Street, NRT-1506

Los Angeles, CA 90089

(323) 442-7865

wiemels@usc.edu

Abstract

The role of race/ethnicity in genetic predisposition of early-onset cancers can be estimated by comparing family-based cancer concordance rates among ethnic groups. We used linked California health registries to evaluate the relative cancer risks for first degree relatives of patients diagnosed between ages 0-26, and the relative risks of developing distinct second malignancies (SPMs). From 1989-2015, we identified 29,631 cancer patients and 62,863 healthy family members. Given probands with cancer, there were increased relative risks of any cancer for siblings and mothers [standardized incidence ratio (SIR)=3.32;95% confidence interval (CI):2.54-4.35;*P*<0.001)]and of SPMs (SIR=7.12;95%CI:5.46-9.28;*P*<0.001). Higher relative risk of any cancer in siblings and mothers (*P*=0.001) was observed for Latinos (SIR=3.36;95%CI:2.24-5.05) compared to non-Latino White subjects (SIR=2.60;95%CI:1.66-4.06). Latinos had higher relative risks in first degree relatives and higher SPM risk compared to non-Latino Whites for most cancers, supporting a need for increased attention to the genetics of early-onset cancer predisposition in Latinos.

(150 words)

Keywords: Early-onset cancer; Familial risk; Linked cancer registry; Race/ethnicity; Latino Americans; Hispanic paradox.

46 **Key Messages**

47 - We identified 29 631 cancer patients and their 62 863 healthy family members in
48 California from 1989 to 2015.
49 - The risk of early-onset cancer in siblings and mothers was elevated by having a proband
50 with cancer in the same family.
51 - The majority of early-onset cancers exhibited higher relative risks in siblings and
52 mothers and second primary malignancies for Latinos when compared to non-Latino
53 Whites.
54
55
56

Introduction

Both genetic and environmental factors play a role in the causes of early-onset cancer. Several well-defined genetic syndromes contribute to early-onset cancer risk, along with a wider array of common alleles that influence risk marginally and detected at the population level. As an example of the former, Li-Fraumeni syndrome caused by mutations in the tumor suppressor gene *TP53*, is associated with an increased risk of a spectrum of cancers diagnosed at early ages[1]. An example of low penetrance common genetic variations associated with cancer risk include *IKZF1* and *ARID5B* genes in pediatric acute lymphoblastic leukemia (ALL)[2]. Both of these classes of variants may vary in frequency by race/ethnic group and cluster by families[3-5], where familial germline deletion of *ETV6* was reported for ALL[6]. Examination of cancer predisposition requires investigation in ethnic strata particularly where cancer incidence rates are known to differ as it does for many pediatric cancer types, such as leukemia[7] and brain cancer[8].

In addition to primary cancers, incidence patterns of second independent malignancies may also provide a perspective of underlying genetic predisposition. Among childhood cancer survivors, more second primary malignancy cases are observed among non-Latino Whites (NLW) than Latino subjects[9]. This is also reflected in adult cancers, where Latino breast cancer survivors had lower risk of second cancers than NLW and NL Black women[10].

Germline pathogenic/likely pathogenic variants in cancer predisposition genes are found in approximately 10% of pediatric cancer patients[1,11-13], and may be inherited or arise *de novo*. Highly penetrant inherited variants will contribute to clustering of cancer cases within the family. Shared environments within the family unit may also be considered alongside genetic risk as potential causes for family-based cancer concordance.

83 Familial concordance of a wide variety of cancers has been assessed using the Swedish
84 Family-Cancer Database, leading to a deep understanding of familial relative risks[14-16]. The
85 Victorian Paediatric Cancer Family Study in Australia also explored the cancer risks for relatives
86 of children with cancer in a small population[17]. In the US, the Utah Population database may be
87 the best-known population for studying familial risk[18-22]. Importantly, these studies largely
88 comprise families of European ancestry, and therefore have not examined potential ethnic-
89 specific familial risks. Here, we utilized linked population registries with over 64,000 individuals
90 to quantify the familial risks (siblings and mothers) and the risks of early-onset second primary
91 malignancies in the highly diverse and large population of California.
92
93
94

Methods

Source of Data

We used linked population-based registries in California to evaluate the relative risks of early-onset cancers (0-26 years age of onset) for siblings and mothers of children, adolescents, and young adults (AYA) aged 0-26 diagnosed with cancer, as well as the relative risks of early-onset second primary malignancies (SPMs) among the proband patients. The dataset was created by linking information from the California Cancer Registry (CCR) and California Birth Statistical Master File, allowing the capture of siblings and parents of cancer probands, along with their cancer incidence. The linked dataset comprehensively encompassed all cancer cases 0-26 years old, as well as their sibling and mother cancers, diagnosed from 1989 to 2015 in California. Our upper age limit of 26 was set based on the available age range covered by this relatively young cohort. Overall, the dataset included a total of 121 571 individuals. The information on healthy siblings and mothers was available during the whole study period, whereas the information on fathers was not available until 2004 in the birth files and therefore is not included in the current analysis.

For the analysis of cancer familial risks, we included all primary incident cancer cases diagnosed from 1989 to 2015 among patients aged 0-26 years, with patient age-at-diagnosis limited by the study time period for which California maintained a statewide SEER gold-standard cancer registry. In addition, we performed a subgroup analysis on pediatric cancers including patients aged 0-15 years diagnosed within the same study period. For the analysis of secondary cancer risks, we included all SPMs diagnosed over the same years and patient age ranges. Although the CCR only records primary malignancies, some misclassification of relapsed or recurrent disease is possible. A physician (E.N.) reviewed diagnosis codes of all the cases diagnosed after the first primary case to prevent the misclassification of relapsed first primary malignancies (FPMs) as SPMs. For both analyses, we classified the cancers into twelve-broad

121 groups and subgroups as defined by the International Classification of Childhood Cancer, Third
122 edition (ICCC-3, November 2012) (https://seer.cancer.gov/iccc/iccc3.html). The abbreviations
123 for cancer types are included in **Table 1**. We also grouped the cancers into hematologic or solid
124 categories in the analyses. Hematologic cancers were defined as leukemias and lymphomas.
125 Solid cancers were defined as CNS tumors, neuroblastomas, retinoblastomas, renal tumors,
126 hepatic tumors, bone tumors, sarcomas, germ cell tumors, epithelial neoplasms and other and
127 unspecified malignant neoplasms.
128
129 ***Statistical Analysis***
130 We quantified the relative risks for siblings and mothers, and the relative risks of SPMs by
131 calculating the standardized incident ratios (SIRs) of a given cancer or of SPMs among the
132 healthy siblings, and the SIRs of a given cancer among healthy mothers of probands using a
133 previous published method[14]. We defined a proband as a pediatric or AYA patient with a given
134 cancer. Only one child/AYA in each family can be a proband, so that in families with two or more
135 cases, the proband is defined as the patient with the earliest date of diagnosis. Given a proband
136 with cancer, we calculated the SIRs for a sibling or a mother in the same family for all types of
137 cancers. Separately, we calculated the SIRs for a sibling for the same type of cancer as the
138 proband. We also stratified the analyses by self-identified race/ethnicity of the mother in each
139 family. The SIRs in siblings, mothers or of SPMs can be denoted as:

140 $$SIR = \frac{O}{E} = \frac{\sum_{i=1}^{N}\sum_{j=1}^{n_i} D_{ij}}{\sum_{i=1}^{N}\sum_{j=1}^{n_i}\sum_{k=1}^{Kmax}\lambda_k t_{ijk}}$$

141 Where N is the number of families, n_i is the number of non-proband individuals of interest
142 (siblings/SPMs/mothers) in family i, and Kmax is the total number of age intervals. The data for
143 each individual includes a disease indicator (D_{ij}) and the number of years "at risk" during the kth
144 age interval (t_{ijk}). A given individual is defined to be at risk beginning at their age when the
145 proband in their family is diagnosed and ending either when they become affected themselves

146 or they are censored due to end of study follow-up. For siblings and mothers, age was stratified
147 into seven groups as 0, 0-4, 5-9, 10-14, 15-19, 20-24 and 25-29 years. For the calculation of
148 SIRs within a given race group, λ_k is the race-, sex- and age-specific incidence rate of a given
149 cancer. We compared the SIRs across race/ethnic groups with approximate Chi-squared tests.
150 The approximate chi-square method compares the probability of occurrence of events in one
151 group to another, based on a binomial distribution. This comparison is not related to the 95%
152 confidence intervals for the SIRs which are based on a Poisson distribution and may overlap
153 between two groups that are significantly different by approximate chi-square comparison. We
154 designated that all events occurred right at the middle point of each calendar year. We also
155 stratified the analysis by 5-year age groups. The 95% confidence intervals (CIs) and p-values
156 were calculated assuming a Poisson distribution. Statistical analyses were performed using R
157 software (v 3.6.0). Any two-sided p-value less than 0.05 was considered statistically significant.
158 A supplement is included with this manuscript with more information on the statistical tests and
159 computational codes used. Please access this supplement "Statistics and coding supplement:
160 Familial_risk_CCR_eLife" for more information.
161
162 **Results**

163 ***Demographics of the study population***

164 From 1989 to 2015, we identified a total of 29 249 pediatric and AYA patients with a primary
165 malignancy, comprising 29 072 probands, 112 affected siblings (from 110 families) and 65
166 affected mothers. All siblings were diagnosed after the proband's diagnosis as defined, and 56
167 (86.15%) of the 65 mothers were diagnosed after the proband's diagnosis. We also identified
168 387 SPMs among all pediatric and AYA probands (**Table 2**).
169

170 ***Familial relative risks of early-onset cancers***

171 Overall, we found a 3.32-fold (95%CI:2.54-4.35) increased relative risk of any cancer among
172 siblings and mothers who have a proband with cancer in the same family. Briefly, we found a
173 2.97-fold (95%CI:1.96-4.50) increased relative risk of any cancer given a proband with
174 hematologic cancers and a 4.54-fold (95%CI:3.19-6.45) increased relative risk of any cancer
175 given a proband with solid cancers. When stratified by cancer types, with the exception of
176 neuroblastomas, hepatic tumors, bone tumors, and malignant neoplasms, proband cancers
177 siblings and mothers were found to have increased SIRs for any cancer (**Figure 1A**).
178
179 For the relative risk of specific cancer types, we found a 2.68-fold (95%CI:1.35-5.32) increased
180 risk of hematologic cancers among siblings and mothers of a proband with hematologic cancer,
181 and a 6.78-fold (95%CI:4.18-10.98) increased relative risk of solid cancers among siblings and
182 mothers of a proband with solid cancer. Furthermore, CNS tumors and epithelial neoplasms
183 exhibited statistically significantly increased relative risk for the same type of cancer as the
184 proband [CNS, SIR=6.19; 95%CI:1.42-26.93; epithelial neoplasms, SIR=40.68; 95%CI: 3.17-
185 521.78] (**Supplementary Table 1**). We also observed increased relative risks for sarcomas
186 (SIR=7.36;95%CI:1.12-48.23) and epithelial neoplasms (SIR=5.37;95%CI:1.52-18.92) given a
187 proband with leukemia, for epithelial neoplasms given a proband with CNS tumors
188 (SIR=6.37;95%CI:1.33-30.41), and for leukemias given a proband with sarcomas
189 (SIR=7.01;95%CI:1.12-43.92) (**Figure 2 & Supplementary Table 1**).
190
191 When stratified by more finely defined cancer subtypes, increased relative risks of any cancer
192 for siblings and mothers were observed given a proband with lymphoid leukemia, acute myeloid
193 leukemia, astrocytoma, certain gliomas, certain specified intracranial and intraspinal neoplasms,
194 nephroblastoma and other nonepithelial renal tumors, rhabdomyosarcomas, certain specified
195 soft tissue sarcomas, malignant gonadal germ cell tumors and certain unspecified carcinomas
196 (**Supplementary Table 4**).

When stratified by race/ethnicity, the relative risk of any cancer for siblings and mothers given a proband with cancer was significantly higher among Latino subjects than non-Latino White (NLW) subjects [Latino: SIR=3.36;95%CI:2.24-5.05; NLW: SIR=2.60;95%CI:1.66-4.06; *P*=0.001]. Non-Latino Asians/Pacific Islanders (API) and Blacks also had higher SIRs than non-Latino Whites (SIR=4.58 and 9.96, respectively, Supplementary Table 2), but small numbers resulted in unstable estimates. Latino subjects also exhibited higher relative risks of any cancer than NLW subjects for solid cancers [Latino: SIR=4.98;95%CI:2.86-8.68; NLW: SIR=3.02;95%CI:1.72-5.28; *P*=0.001], while NLW subjects exhibited higher relative risks than Latino subjects for hematologic cancers [Latino: SIR=2.48;95%CI:1.37-4.50; NLW: SIR=2.69;95%CI:1.29-5.62; *P*=0.016] (**Figure 1B & Supplementary Table 2**). For the relative risk of specific cancers given a proband with the same cancer, Latino subjects showed higher relative risk of solid cancers than NLW subjects [Latino: SIR=7.94;95%CI:3.64-17.34; NLW: SIR=4.41;95%CI:2.10-9.23; *P*=0.005] (**Supplementary Table 3**).

In the subgroup analysis of pediatric patients aged 0-15 years, we observed a similar trend where the relative risk of any cancer for siblings and mothers was significantly higher among Latino subjects than NLW subjects [Latino: SIR=1.51;95%CI:1.00-2.26; NLW: SIR=0.93;95%CI:0.60-1.46; *P*=0.003] (**Supplementary Table 5**).

Relative risks of second primary malignancies

Overall, we found a 7.12-fold increased risk of SPMs relative to the general population among children/AYAs with an FPM (SIR=7.12;95%CI:5.46-9.28). Most primary cancer types were associated with an elevated relative risk of SPMs (**Figure 3A**). When stratified by race/ethnicity, slightly higher relative risk of all SPMs given a proband with cancer was observed among Latino

222 subjects than NLW subjects [Latino: SIR=6.85;95%CI:4.56-10.30; NLW: SIR=6.67;95%CI:4.26-
223 10.43; *P*=0.001] (**Figure 3B**).
224
225 For the relative risks of SPMs of the same cancer types as the FPM, we found elevated risks for
226 both hematologic and solid cancers. When stratified by race/ethnicity, higher relative risk of
227 hematologic cancers was observed among NLW subjects compared to Latino subjects given a
228 proband with hematologic cancers [Latino: SIR=4.23;95%CI:1.68-10.68; NLW:
229 SIR=6.61;95%CI:1.80-24.29; *P*=0.012] (**Supplementary Table 6**).
230

231 **Discussion**

232 To our knowledge, this is the first study to quantify the familial clustering risks and risks of SPMs
233 among early-onset cancer patients with an emphasis on racial/ethnic differences. Using linked
234 population registry data in the California population, we found that the risk for a sibling
235 child/AYA or mother to have early-onset cancer was elevated once a proband was identified
236 with an early-onset cancer. Likewise, the relative risks for SPMs were elevated among
237 children/AYAs who contracted a first primary cancer. The findings were consistent across
238 race/ethnic groups; however, the magnitude was different. Latinos had higher sibling/maternal
239 relative risks as well as risks for SPMs compared to NLWs for most cancers.
240

241 Consistent with our results, a rich literature with a primary focus on European ancestry
242 populations has reported excessive familial risks of hematologic malignancies[14], lymphomas[23-
243 25], brain tumors[26,27], neuroblastomas[28], retinoblastomas[25,28], germ cell tumors[29], sarcomas[30] and
244 melanomas[31]. In terms of secondary cancers, studies have reported excessive risks of second
245 primary malignancies among of survivors of hereditary retinoblastoma[32], chronic myeloid
246 leukemia[33], chronic lymphocytic leukemia[34], Hodgkin's lymphoma[35], non- Hodgkin's
247 lymphoma[36], and neuroblastoma[37]. The excessive familial risks of certain cancers are highly
248 likely to be associated with genetic predisposition. The archetypic examples are germline loss-
249 of-function mutations in *RB1*, which are found in ~40% of retinoblastoma cases[28], and adrenal
250 cortical cancer, with germline *TP53* mutations accounting for most familial cases[28]. Low
251 penetrance common genetic variations, for instance in *CEBPE*, *IKZF1*, and *ARID5B* genes in
252 ALL, are associated with cancer risk and may also contribute to familial concordance as
253 combinations of low frequency alleles or “polygenic risk scores” have been shown to be as
254 impactful as single strong predisposition mutations in adult cancers[38,39]; however, their
255 contribution to cancer clustering among children and their families has not yet been studied.
256

257 Our data demonstrate a higher degree of familial-based clustering among Latinos compared to
258 non-Latino Whites. This familial concordance is likely due to both shared genetic and
259 environmental causes and is accompanied by a clearly higher incidence of some cancer types.
260 Latinos are an admixed population, comprising an ancestral mixture from Native American,
261 European, and African sources. California Latinos, particularly the youth population are largely
262 from Mexico, and harbor a higher risk of certain cancers particularly pediatric leukemias, the
263 most common cancer in children[40]; however this higher risk is partially accounted for by a higher
264 frequency of common risk alleles which do not address strong familial predisposition loci[4]. This
265 higher risk identified in relation to the family unit has not been studied, and our results here beg
266 for an analysis of comparative sources of genetic and environmental risk that contribute to the
267 higher risk and familial clustering of cancers in Latinos.
268
269 Therapy of the first primary cancer is a major factor in the induction of secondary independent
270 malignancies[41-43]. The purpose of radiation and chemo-therapies of cancer patients is to
271 improve survivorship. In the current analysis, better survivorship of hematologic cancers for non-
272 Latino Whites compared to Latinos may however contribute to the excessive risk of second
273 primary malignancies among White subjects[44], as some Latino subjects with hematologic
274 cancers may not have survived long enough to develop a secondary cancer. Nevertheless,
275 multiple primary cancer diagnoses are considered a key feature of hereditary cancer
276 predisposition syndromes[45]. As such secondary cancers are rare, genetics are still likely to play
277 a strong role[46], and our overall SPM results here emphasize a similar ethnic-specific patterning
278 as cancer clustering in first primary malignancies. Of note, our analysis was not designed to
279 distinguish relative risk contributions from therapy and genetic sources for secondary cancers.
280
281 For some tumor types the germline predisposition was readily noted in this cohort, for example
282 ten of the fourteen affected relatives who had a proband with retinoblastoma were diagnosed

283 with the same cancer, an unsurprising finding given that germline *RB1* mutations account for a
284 significant proportion of retinoblastoma are highly penetrant and those tumors tend to be
285 diagnosed young. We also observed increased relative risks for sarcomas given a proband with
286 leukemias, suggesting the presence of families with Li-Fraumeni syndrome, which is
287 characterized by a spectrum of childhood and adult-onset cancers including adrenocortical
288 carcinoma, breast cancer, CNS tumors, sarcomas, and leukemia[45].
289
290 Population-level selection pressures are thought to influence the relative frequencies of alleles.
291 For instance, genetic adaptations that shaped the Native American genome to cold and warm
292 environments[47], and immune response following colonization by Europeans[48]. Our result
293 suggests that some adaptive selection pressures, or simply genetic drift exacerbated by
294 bottlenecking of genetic diversity during the Native American population history may
295 differentially influence familial cancer clustering by age of cancer onset[49]. If replicated in other
296 study settings, this contrast between genetic risk child and adult onset cancers by ethnicity
297 should be studied further for a fuller understanding of familial risks.
298
299 Our analyses capitalized on the highly diverse population in California, allowing us to quantify
300 the relative risks across different ethnic groups. Moreover, the utilization of linked population-
301 based registries in California enabled us to minimize the selection and information biases
302 introduced by a case-control study design or other strategies that only sample portions of the
303 population. Furthermore, although Latinos usually have more people per household than
304 NLWs[50], detection bias of cancers among siblings and mothers is less likely, which is reflected
305 by the excessive relative risk of lymphomas among NLW compared to Latino subjects in the
306 current analysis in agreement with previous reports[51,52]. There are also some limitations of our
307 study. Despite the large number of total cancer cases, the number of affected siblings and
308 second primaries are very small for some cancer types, thus limiting the power to detect

309 significant relative risks. Also, we are unable to track cancer incidence for affected siblings,
310 maternal cancers, and SPMs that may have been diagnosed outside of California. In addition,
311 the follow-up time of 26 years is not enough for a comprehensive detection of SPMs in the
312 probands, nor for cancers arising in proband mothers at older ages. These insufficient follow-up
313 time and loss-to follow-up issues have limited our ability to quantify the relative risks among
314 mothers with cancer onset at older ages (>40 yrs). Lastly, the lack of records on fathers reduces
315 our ability to quantify the relative risks among other first-degree relatives and may reduce the
316 appreciation of the potential contribution of high-risk cancer predisposition syndromes which can
317 be inherited from either parent.
318
319 Accepting those limitations with the current dataset, our study has several important implications
320 that may open windows to future research. First, the genetic predispositions driving the
321 excessive childhood cancer risks among the Latino population, whether from higher frequencies
322 of known cancer predisposition syndromes or mutations in novel genes, or a higher burden of
323 common or rare genetic risk alleles, warrants further investigation. Second, the comparative
324 attributable fraction of familial risk based on environmental risk factors interacting with genetic
325 predispositions warrants further investigation. Lastly, descriptive studies on familial and
326 secondary cancer risks among race/ethnic groups other than Latinos and non-Latino Whites
327 may provide additional insights into cancer incidence variation by race/ethnicity.
328
329 (2939 words)

Funding

This work was supported by the V Foundation for funding this work (Grant FP067172). The collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute's Surveillance, Epidemiology, and End Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute; and the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement U58DP003862-01 awarded to the California Department of Public Health. The ideas and opinions expressed herein are those of the author(s), and no endorsement by the California Department of Public Health, the National Cancer Institute, or the Centers for Disease Control and Prevention or their contractors and subcontractors is intended or should be inferred.

Declaration of interests

None.

347 **References**

348 1. Saletta F, Dalla Pozza L, Byrne JA. Genetic causes of cancer predisposition in children
349 and adolescents. *Transl Pediatr.* 2015;4(2):67-75.
350 2. Moriyama T, Relling MV, Yang JJ. Inherited genetic variation in childhood acute
351 lymphoblastic leukemia. *Blood.* 2015;125(26):3988-3995.
352 3. Caswell-Jin JL, Gupta T, Hall E, et al. Racial/ethnic differences in multiple-gene
353 sequencing results for hereditary cancer risk. *Genet Med.* 2018;20(2):234-239.
354 4. Walsh KM, Chokkalingam AP, Hsu LI, et al. Associations between genome-wide Native
355 American ancestry, known risk alleles and B-cell ALL risk in Hispanic children.
356 *Leukemia.* 2013;27(12):2416-2419.
357 5. Ricker C, Culver JO, Lowstuter K, et al. Increased yield of actionable mutations using
358 multi-gene panels to assess hereditary cancer susceptibility in an ethnically diverse
359 clinical cohort. *Cancer Genet.* 2016;209(4):130-137.
360 6. Rampersaud E, Ziegler DS, Iacobucci I, et al. Germline deletion of ETV6 in familial acute
361 lymphoblastic leukemia. *Blood Adv.* 2019;3(7):1039-1046.
362 7. Feng Q, de Smith AJ, Vergara-Lluri M, et al. Trends in Acute Lymphoblastic Leukemia
363 Incidence in the US from 2000-2016: an Increased Risk in Latinos Across All Age
364 Groups. In. *Am J Epidemiol.* Vol In press2020.
365 8. Ostrom QT, Adel Fahmideh M, Cote DJ, et al. Risk factors for childhood and adult
366 primary brain tumors. *Neuro Oncol.* 2019;21(11):1357-1375.
367 9. Brown AL, Arroyo VM, Agrusa JE, Scheurer ME, Gramatges MM, Lupo PJ. Survival
368 disparities for second primary malignancies diagnosed among childhood cancer
369 survivors: A population-based assessment. *Cancer.* 2019;125(20):3623-3630.
370 10. Calip GS, Law EH, Ko NY. Racial and ethnic differences in risk of second primary
371 cancers among breast cancer survivors. *Breast Cancer Res Treat.* 2015;151(3):687-696.
372 11. Zhang J, Walsh MF, Wu G, et al. Germline Mutations in Predisposition Genes in
373 Pediatric Cancer. *N Engl J Med.* 2015;373(24):2336-2346.
374 12. Plon SE, Lupo PJ. Genetic Predisposition to Childhood Cancer in the Genomic Era.
375 *Annu Rev Genomics Hum Genet.* 2019;20:241-263.
376 13. Ripperger T, Bielack SS, Borkhardt A, et al. Childhood cancer predisposition syndromes-
377 A concise review and recommendations by the Cancer Predisposition Working Group of
378 the Society for Pediatric Oncology and Hematology. *Am J Med Genet A.*
379 2017;173(4):1017-1037.
380 14. Sud A, Chattopadhyay S, Thomsen H, et al. Analysis of 153 115 patients with
381 hematological malignancies refines the spectrum of familial risk. *Blood.*
382 2019;134(12):960-969.
383 15. Kharazmi E, Fallah M, Sundquist K, Hemminki K. Familial risk of early and late onset
384 cancer: nationwide prospective cohort study. *BMJ.* 2012;345:e8076.
385 16. Hemminki K, Czene K. Attributable risks of familial cancer from the Family-Cancer
386 Database. *Cancer Epidemiol Biomarkers Prev.* 2002;11(12):1638-1644.
387 17. Heath JA, Smibert E, Algar EM, Dite GS, Hopper JL. Cancer risks for relatives of
388 children with cancer. *J Cancer Epidemiol.* 2014;2014:806076.
389 18. Curtin K, Smith KR, Fraser A, Pimentel R, Kohlmann W, Schiffman JD. Familial risk of
390 childhood cancer and tumors in the Li-Fraumeni spectrum in the Utah Population
391 Database: implications for genetic evaluation in pediatric practice. *Int J Cancer.*
392 2013;133(10):2444-2453.
393 19. Kohli DR, Smith KR, Wong J, et al. Familial pancreatic cancer risk: a population-based
394 study in Utah. *J Gastroenterol.* 2019;54(12):1106-1112.

395 20. Samadder NJ, Curtin K, Wong J, et al. Epidemiology and familial risk of synchronous
396 and metachronous colorectal cancer: a population-based study in Utah. *Clin*
397 *Gastroenterol Hepatol.* 2014;12(12):2078-2084 e2071-2072.
398 21. Wang X, Harmon J, Zabrieskie N, et al. Using the Utah Population Database to assess
399 familial risk of primary open angle glaucoma. *Vision Res.* 2010;50(23):2391-2395.
400 22. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-
401 based assessment of cancer risk in first-degree relatives of cancer probands. *J Natl*
402 *Cancer Inst.* 1994;86(21):1600-1608.
403 23. Cerhan JR, Slager SL. Familial predisposition and genetic risk factors for lymphoma.
404 *Blood.* 2015;126(20):2265-2273.
405 24. Fallah M, Kharazmi E, Pukkala E, et al. Familial risk of non-Hodgkin lymphoma by sex,
406 relationship, age at diagnosis and histology: a joint study from five Nordic countries.
407 *Leukemia.* 2016;30(2):373-378.
408 25. Madanat-Harjuoja LM, Pitkaniemi J, Hirvonen E, Malila N, Diller LR. Linking population-
409 based registries to identify familial cancer risk in childhood cancer. *Cancer.*
410 2020;126(13):3076-3083.
411 26. Couldwell WT, Cannon-Albright LA. A description of familial clustering of meningiomas in
412 the Utah population. *Neuro Oncol.* 2017;19(12):1683-1687.
413 27. Crump C, Sundquist J, Sieh W, Winkleby MA, Sundquist K. Perinatal and familial risk
414 factors for brain tumors in childhood through young adulthood. *Cancer Res.*
415 2015;75(3):576-583.
416 28. Kamihara J, Bourdeaut F, Foulkes WD, et al. Retinoblastoma and Neuroblastoma
417 Predisposition and Surveillance. *Clin Cancer Res.* 2017;23(13):e98-e106.
418 29. Landero-Huerta DA, Vigueras-Villasenor RM, Yokoyama-Rebollar E, et al. Epigenetic
419 and risk factors of testicular germ cell tumors: a brief review. *Front Biosci (Landmark*
420 *Ed).* 2017;22:1073-1098.
421 30. Lynch HT, Deters CA, Hogg D, Lynch JF, Kinarsky Y, Gatalica Z. Familial sarcoma:
422 challenging pedigrees. *Cancer.* 2003;98(9):1947-1957.
423 31. Frank C, Sundquist J, Hemminki A, Hemminki K. Risk of other Cancers in Families with
424 Melanoma: Novel Familial Links. *Sci Rep.* 2017;7:42601.
425 32. Marees T, Moll AC, Imhof SM, de Boer MR, Ringens PJ, van Leeuwen FE. Risk of
426 second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. *J*
427 *Natl Cancer Inst.* 2008;100(24):1771-1779.
428 33. Sasaki K, Kantarjian HM, O'Brien S, et al. Incidence of second malignancies in patients
429 with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. *Int J Hematol.*
430 2019;109(5):545-552.
431 34. Molica S. Second neoplasms in chronic lymphocytic leukemia: incidence and
432 pathogenesis with emphasis on the role of different therapies. *Leuk Lymphoma.*
433 2005;46(1):49-54.
434 35. Baker H. Second cancer risk for Hodgkin's lymphoma survivors. *Lancet Oncol.*
435 2016;17(2):e50.
436 36. Chattopadhyay S, Sud A, Zheng G, et al. Second primary cancers in non-Hodgkin
437 lymphoma: Bidirectional analyses suggesting role for immune dysfunction. *Int J Cancer.*
438 2018;143(10):2449-2457.
439 37. Applebaum MA, Henderson TO, Lee SM, Pinto N, Volchenboum SL, Cohn SL. Second
440 malignancies in patients with neuroblastoma: the effects of risk-based therapy. *Pediatr*
441 *Blood Cancer.* 2015;62(1):128-133.
442 38. Fantus RJ, Helfand BT. Germline Genetics of Prostate Cancer: Time to Incorporate
443 Genetics into Early Detection Tools. *Clin Chem.* 2019;65(1):74-79.
444 39. Yadav S, Couch FJ. Germline Genetic Testing for Breast Cancer Risk: The Past,
445 Present, and Future. *Am Soc Clin Oncol Educ Book.* 2019;39:61-74.

40. Barrington-Trimis JL, Cockburn M, Metayer C, Gauderman WJ, Wiemels J, McKean-Cowdin R. Trends in childhood leukemia incidence over two decades from 1992 to 2013. *Int J Cancer.* 2017;140(5):1000-1008.
41. McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. *Nat Rev Cancer.* 2017;17(9):513-527.
42. Mazonakis M, Kachris S, Damilakis J. Second Cancer Risk from Radiation Therapy for Common Solid Tumors Diagnosed in Reproductive-Aged Females. *Radiat Prot Dosimetry.* 2018;182(2):208-214.
43. Turcotte LM, Liu Q, Yasui Y, et al. Chemotherapy and Risk of Subsequent Malignant Neoplasms in the Childhood Cancer Survivor Study Cohort. *J Clin Oncol.* 2019;37(34):3310-3319.
44. Kirtane K, Lee SJ. Racial and ethnic disparities in hematologic malignancies. *Blood.* 2017;130(15):1699-1705.
45. Valdez JM, Nichols KE, Kesserwan C. Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition. *Br J Haematol.* 2017;176(4):539-552.
46. Churpek JE, Marquez R, Neistadt B, et al. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. *Cancer.* 2016;122(2):304-311.
47. Reynolds AW, Mata-Miguez J, Miro-Herrans A, et al. Comparing signals of natural selection between three Indigenous North American populations. *Proc Natl Acad Sci U S A.* 2019;116(19):9312-9317.
48. Lindo J, Huerta-Sanchez E, Nakagome S, et al. A time transect of exomes from a Native American population before and after European contact. *Nat Commun.* 2016;7:13175.
49. O'Fallon BD, Fehren-Schmitz L. Native Americans experienced a strong population bottleneck coincident with European contact. *Proc Natl Acad Sci U S A.* 2011;108(51):20444-20448.
50. bureau USC. Historical Households Tables. https://www.census.gov/data/tables/time-series/demo/families/households.html. Published 2019. Accessed.
51. Center PR. Latinos in California, Texas, New York, Florida and New Jersey. https://www.pewresearch.org/hispanic/2004/03/19/latinos-in-california-texas-new-york-florida-and-new-jersey/. Published 2004. Accessed.
52. Adams SV, Newcomb PA, Shustov AR. Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States. *J Clin Oncol.* 2016;34(9):963-971.

481 **Tables**

482 Table 1. Abbreviations of the twelve broad groups defined by the International Classification of
483 Childhood Cancer, Third edition.

484

Abbreviation	Definition †
Leukemias	I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases
Lymphomas	II. Lymphomas and reticuloendothelial neoplasms
CNS tumors	III. CNS and miscellaneous intracranial and intraspinal neoplasms
Neuroblastomas	IV. Neuroblastoma and other peripheral nervous cell tumors
Retinoblastoma	V. Retinoblastoma
Renal tumors	VI. Renal tumors
Hepatic tumors	VII. Hepatic tumors
Bone tumors	VIII. Malignant bone tumors
Sarcomas	IX. Soft tissue and other extraosseous sarcomas
GCT	X. Germ cell tumors, trophoblastic tumors, and neoplasms of gonads
Epithelial neoplasms	XI. Other malignant epithelial neoplasms and malignant melanomas
Other	XII. Other and unspecified malignant neoplasms

485 † Cancers were classified into groups as defined by the International Classification of Childhood
486 Cancer, Third edition (ICCC-3, November 2012) (https://seer.cancer.gov/iccc/iccc3.html).

487

488

Table 2. Selected demographic characteristic of probands, affected siblings and second primary malignancies among the early-onset cancer patients in the linked population-based registries in California, 1989 to 2015.

	No. (%)				
	Overall *	No. of probands	No. of affected siblings	No. of affected mothers	No. of second primaries †
Overall	29 249	29 072	112	65	387
Age at diagnosis (years) ‡					
0	2592 (8.75)	2611 (8.98)	10 (8.93)	0 (0.00)	4 (1.03)
1-4	8683 (29.3)	8719 (29.99)	15 (13.39)	2 (3.08)	37 (9.56)
5-9	5054 (17.06)	5057 (17.39)	12 (10.71)	0 (0.00)	67 (17.31)
10-14	4224 (14.26)	4180 (14.38)	22 (19.64)	0 (0.00)	98 (25.32)
15-19	4734 (15.98)	4664 (16.04)	37 (33.04)	7 (10.77)	90 (23.26)
20+	4344 (14.66)	3841 (13.21)	16 (14.29)	56 (86.15)	91 (23.51)
Gender					
Male	15 528 (52.40)	15 467 (53.20)	56 (50.00)	NA	198 (51.16)
Female	14 102 (47.59)	13 605 (46.80)	56 (50.00)	65 (100.00)	189 (48.84)
Race/ethnicity					
Latino (all races)	13 281 (44.82)	13 059 (44.92)	51 (45.54)	26 (40.00)	159 (41.09)
Non-Latino White	11 410 (38.51)	11 193 (38.50)	39 (34.82)	17 (26.15)	128 (33.07)
Non-Latino Black	1772 (5.98)	1716 (5.90)	9 (8.04)	7 (10.77)	10 (2.58)
Non-Latino Asian/Pacific Islander	2605 (8.79)	2551 (8.77)	12 (10.71)	0 (0.00)	47 (12.14)
Other	563 (1.94)	553 (1.90)	1 (0.89)	15 (4.62)	43 (11.11)

* All early-onset cancer patients diagnosed from 1989 to 2015 identified in the linked population-based registries in California.

† Number of second primary malignancies diagnosed from 1989 to 2015 within all children (probands and affected siblings, excluding mothers) with early-onset cancers in the linked population-based registries in California.

Figures

Figure legend:

Figure 1: Relative risks of early-onset cancers among siblings and mothers.
A. Relative risks among siblings and mothers of any early-onset cancer (diagnosed under 26 years of age) given a proband with cancer, 1989 to 2015, California, USA.
B. Relative risks by ethnic group among siblings and mothers of any early-onset cancer (diagnosed under 26 years of age) given a proband with cancer, 1989 to 2015, California, USA.

Cancers were classified into groups as defined by the International Classification of Childhood Cancer, Third edition (ICCC-3, November 2012) (https://seer.cancer.gov/iccc/iccc3.html). Hematologic cancers include leukemias and lymphomas. Solid cancers include CNS tumors, neuroblastomas, retinoblastomas, renal tumors, hepatic tumors, bone tumors, sarcomas, GCT, epithelial neoplasms and others.

The axis for SIR was natural log-transformed. SIR and 95% CI were not calculatable for cancers with zero observed case.
P was calculated assuming a Poisson distribution.
Abbreviations: SIR, Standardized incidence ratio. CI, confidence interval. GCT, germ cell tumors, trophoblastic tumors, and neoplasms of gonads.

Figure 2: Relative risks of siblings and mothers of specific cancers.
Cancers were classified into groups as defined by the International Classification of Childhood Cancer, Third edition (ICCC-3, November 2012) (https://seer.cancer.gov/iccc/iccc3.html). Standardized incidence ratios greater than 10 were recoded to 10.
Siblings and mothers of a proband were diagnosed with cancer from 1989 to 2015 at 0 to 26 years of age.
P was calculated assuming a Poisson distribution.
Abbreviations: SIR, Standardized incidence ratio. CI, confidence interval. GCT, germ cell tumors, trophoblastic tumors, and neoplasms of gonads.

Figure 3. Relative risks of second primary malignancies.
A. Relative risks of second primary malignancies of any early-onset cancer (diagnosed under 26 years of age) given a proband with cancer, 1989 to 2015, California, USA.
B. Relative risks of second primary malignancies of any early-onset cancer (diagnosed under 26 years of age) given a proband with cancer by ethnic group, 1989 to 2015, California, USA.

Cancers were classified into groups as defined by the International Classification of Childhood Cancer, Third edition (ICCC-3, November 2012) (https://seer.cancer.gov/iccc/iccc3.html). Hematologic cancers include leukemias and lymphomas. Solid cancers include CNS tumors, neuroblastomas, retinoblastomas, renal tumors, hepatic tumors, bone tumors, sarcomas, GCT, epithelial neoplasms and others.

The axis for SIR was natural log-transformed. SIR and 95% CI were not calculatable for cancers with zero observed case.
P was calculated assuming a Poisson distribution.
Abbreviations: SIR, Standardized incidence ratio. CI, confidence interval. GCT, germ cell tumors, trophoblastic tumors, and neoplasms of gonads. FPM, first primary malignancy. SPM, second primary malignancy.

551
552
553 Figure 1A.

Group	No. of probands	No. of affected siblings and mothers	SIR of any cancer (95% CI)	P
Overall	29072	177	3.32 (2.54, 4.35)	<0.001
Hematologic cancers	11404	66	2.97 (1.96, 4.50)	<0.001
Solid cancers	17849	141	4.54 (3.19, 6.45)	<0.001
Leukemias	8500	51	2.87 (1.80, 4.57)	<0.001
Lymphomas	2928	21	4.66 (1.85, 11.75)	0.065
CNS tumors	5739	38	3.50 (1.93, 6.34)	0.002
Neuroblastomas	1445	7	2.01 (0.70, 5.76)	0.119
Retinoblastomas	718	14	8.03 (1.82, 35.43)	0.355
Renal tumors	1069	9	3.62 (1.04, 12.57)	0.220
Hepatic tumors	414	2	2.20 (0.28, 17.16)	0.622
Bone tumors	249	2	5.59 (0.21, 148.04)	0.891
Sarcomas	2915	40	7.85 (3.30, 18.72)	0.050
GCT	2423	20	5.97 (2.05, 17.41)	0.128
Epithelial neoplasms	3050	36	12.51 (3.94, 39.71)	0.171
Other	255	4	9.18 (0.47, 179.03)	0.851



554
555 Figure 1B.
556

Group	Non-Latino White SIR of any cancer (95% CI)	P	Latino all races SIR of any cancer (95% CI)	P	P comparing SIRs
Overall	2.60 (1.66, 4.06)	<0.001	3.36 (2.24, 5.05)	<0.001	0.001
Hematologic cancers	2.69 (1.29, 5.62)	0.015	2.48 (1.37, 4.50)	0.002	0.016
Solid cancers	3.02 (1.72, 5.28)	0.001	4.98 (2.86, 8.68)	0.001	0.001
Leukemias	2.11 (0.89, 4.96)	0.050	2.35 (1.22, 4.53)	0.005	0.004
Lymphomas	4.32 (1.02, 18.25)	0.331	4.10 (1.01, 16.64)	0.308	0.88
CNS tumors	2.63 (1.05, 6.58)	0.062	2.86 (1.10, 7.43)	0.076	0.767
Neuroblastomas	0.70 (0.14, 3.64)	0.441	1.70 (0.28, 10.32)	0.517	0.455
Retinoblastomas	3.65 (0.26, 51.45)	0.792	12.32 (1.24, 121.98)	0.702	0.016
Renal tumors	2.64 (0.28, 25.14)	0.690	2.91 (0.42, 20.03)	0.572	0.463
Hepatic tumors			2.43 (0.11, 51.51)	0.863	0.311
Bone tumors			6.06 (0.05, 755.63)	0.977	0.306
Sarcomas	3.77 (0.89, 15.87)	0.329	9.06 (2.42, 33.86)	0.262	0.003
GCT	3.42 (0.56, 20.99)	0.522	6.20 (1.32, 29.04)	0.387	0.04
Epithelial neoplasms	8.60 (1.85, 39.96)	0.383	15.16 (2.11, 108.71)	0.589	0.032
Other	10.49 (0.12, 932.36)	0.968	5.86 (0.05, 673.74)	0.975	0.313



557
558
559
560
561
562
563
564

565 Figure 2.



566
567
568

569 Figure 3A.

Group	No. of FPMs	No. of SPMs	SIR of any cancer (95% CI)	P
Overall	30059	387	7.12 (5.46 to 9.28)	<0.001
Hematologic cancers	11553	146	6.57 (4.33, 9.95)	<0.001
Solid cancers	18893	241	7.75 (5.45, 11.02)	<0.001
Leukemias	8543	116	6.38 (4.03 to 10.10)	<0.001
Lymphomas	2960	30	6.42 (2.59 to 15.90)	0.050
CNS tumors	5877	64	5.76 (3.20 to 10.37)	0.002
Neuroblastomas	1450	24	6.76 (2.39 to 19.12)	0.113
Retinoblastomas	728	24	13.48 (3.10 to 58.59)	0.346
Renal tumors	1078	13	5.09 (1.49 to 17.35)	0.210
Hepatic tumors	417	5	5.38 (0.70 to 41.12)	0.614
Bone tumors	250	8	21.56 (0.86 to 538.54)	0.884
Sarcomas	3028	68	12.90 (5.49 to 30.29)	0.041
GCT	2468	13	3.73 (1.31 to 10.65)	0.117
Epithelial neoplasms	3479	21	6.94 (2.25 to 21.44)	0.157
Other	261	1	2.22 (0.12 to 41.05)	0.843



570
571
572 Figure 3B.

Group	Non-Latino White SIR of any cancer (95% CI)	P	Latino all races SIR of any cancer (95% CI)	P	P comparing SIRs
Overall	6.67 (4.26 to 10.43)	<0.001	6.85 (4.56 to 10.30)	<0.001	0.001
Hematologic cancers	5.80 (2.78, 12.12)	0.015	5.61 (3.10, 10.17)	0.002	<0.001
Solid cancers	7.09 (4.05, 12.41)	0.001	7.87 (4.52, 13.72)	0.001	0.263
Leukemias	5.18 (2.20 to 12.23)	0.043	5.60 (2.91 to 10.79)	0.005	<0.001
Lymphomas	7.58 (1.79 to 32.09)	0.332	5.64 (1.39 to 22.92)	0.309	0.357
CNS tumors	5.71 (2.28 to 14.30)	0.062	6.43 (2.47 to 16.75)	0.077	0.639
Neuroblastomas	9.17 (1.77 to 47.54)	0.441	3.40 (0.56 to 20.66)	0.518	<0.001
Retinoblastomas	9.14 (0.65 to 129.39)	0.793	10.96 (1.11 to 108.65)	0.703	<0.001
Renal tumors	9.27 (0.97 to 88.47)	0.691	2.91 (0.42 to 20.05)	0.573	<0.001
Hepatic tumors			9.71 (0.46 to 205.74)	0.863	
Bone tumors	16.95 (0.06 to 5094.92)	0.991	18.18 (0.15 to 2265.63)	0.977	0.454
Sarcomas	10.25 (2.43 to 43.27)	0.330	14.50 (3.88 to 54.24)	0.262	0.014
GCT	3.43 (0.56 to 21.10)	0.523	4.97 (1.06 to 23.29)	0.388	0.112
Epithelial neoplasms	6.78 (1.46 to 31.57)	0.384	8.10 (1.13 to 58.17)	0.590	0.043
Other			5.88 (0.05 to 682.43)	0.976	



573
574
575
576
577
578
579
580
581